[go: up one dir, main page]

CU23404A1 - NEISSERIA MENINGITIDIS CAPSULAR POLYSACARIDS AS MUCOSOPT IMMUNOPOTENTIZERS AND RESULTING FORMULATIONS - Google Patents

NEISSERIA MENINGITIDIS CAPSULAR POLYSACARIDS AS MUCOSOPT IMMUNOPOTENTIZERS AND RESULTING FORMULATIONS

Info

Publication number
CU23404A1
CU23404A1 CU20030270A CU20030270A CU23404A1 CU 23404 A1 CU23404 A1 CU 23404A1 CU 20030270 A CU20030270 A CU 20030270A CU 20030270 A CU20030270 A CU 20030270A CU 23404 A1 CU23404 A1 CU 23404A1
Authority
CU
Cuba
Prior art keywords
polysaccharides
formulations
neisseria meningitidis
meningitidis
similar
Prior art date
Application number
CU20030270A
Other languages
Spanish (es)
Inventor
Blanco Sonia Gonzalez
Portilla Tania Carmenate
Espina Maite Delgado
Perez Olivia Niebla
Garcia Gretel Sardinas
Feyt Rolando Pajon
Rubido Julio Cesar Aguilar
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20030270A priority Critical patent/CU23404A1/en
Priority to ARP040104182A priority patent/AR046840A1/en
Priority to PCT/CU2004/000014 priority patent/WO2005049076A1/en
Publication of CU23404A1 publication Critical patent/CU23404A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de polisacáridos capsulares de distintos serogrupos de Neisseria meningitidis, como agentes inmunopotenciadores e inmunomodulares, útiles para el desarrollo de vacunas. En la presente invención se administran dichos polisacáridos para incrementar la respuesta inmune contra antígenos heterólogos que han sido coadministrados por la vía muscusal. Se obtienen formulaciones múltiples de los polisacáridos capsulares de N. Meningitidis y antígenos heterólogos que al ser administradas por vías mucosales, producen niveles de inmunogenicidad similares a los obtenidos después de la administración parenteral de combinaciones similares a los obtenidos después de la administración parenteral de combinaciones similares. El uso de dichos polisacáridos como inmunopotenciadores permite prescindir del empleo de otros adyuvantes mucosales. Este nuevo uso de los polisacáridos capsulares de N. meningitidis y las formulaciones antigénicas resultantes son aplicables en la industria farmacéutica como formulaciones vacúnales preventivas o terapéuticas.Use of capsular polysaccharides from different serogroups of Neisseria meningitidis, as immunopotentiating and immunomodular agents, useful for vaccine development. In the present invention, said polysaccharides are administered to increase the immune response against heterologous antigens that have been coadministered by the muscle route. Multiple formulations of the capsular polysaccharides of N. Meningitidis and heterologous antigens are obtained which, when administered by mucosal routes, produce immunogenicity levels similar to those obtained after parenteral administration of combinations similar to those obtained after parenteral administration of similar combinations. . The use of said polysaccharides as immunopotentiators makes it possible to dispense with the use of other mucosal adjuvants. This new use of N. meningitidis capsular polysaccharides and the resulting antigenic formulations are applicable in the pharmaceutical industry as preventive or therapeutic vaccine formulations.

CU20030270A 2003-11-19 2003-11-19 NEISSERIA MENINGITIDIS CAPSULAR POLYSACARIDS AS MUCOSOPT IMMUNOPOTENTIZERS AND RESULTING FORMULATIONS CU23404A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CU20030270A CU23404A1 (en) 2003-11-19 2003-11-19 NEISSERIA MENINGITIDIS CAPSULAR POLYSACARIDS AS MUCOSOPT IMMUNOPOTENTIZERS AND RESULTING FORMULATIONS
ARP040104182A AR046840A1 (en) 2003-11-19 2004-11-12 CAPSULAR POLISACARIDS OF NEISSERIA MENINGITIDIS AS MUCOSOPT IMMUNOPOTENCERS AND RESULTING FORMULATIONS
PCT/CU2004/000014 WO2005049076A1 (en) 2003-11-19 2004-11-18 Use of capsular neisseria meningitidis polysaccharides as mucosal immunopotentiators and resulting formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20030270A CU23404A1 (en) 2003-11-19 2003-11-19 NEISSERIA MENINGITIDIS CAPSULAR POLYSACARIDS AS MUCOSOPT IMMUNOPOTENTIZERS AND RESULTING FORMULATIONS

Publications (1)

Publication Number Publication Date
CU23404A1 true CU23404A1 (en) 2009-08-04

Family

ID=34777988

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20030270A CU23404A1 (en) 2003-11-19 2003-11-19 NEISSERIA MENINGITIDIS CAPSULAR POLYSACARIDS AS MUCOSOPT IMMUNOPOTENTIZERS AND RESULTING FORMULATIONS

Country Status (3)

Country Link
AR (1) AR046840A1 (en)
CU (1) CU23404A1 (en)
WO (1) WO2005049076A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7648997B2 (en) 2003-08-12 2010-01-19 Coley Pharmaceutical Group, Inc. Hydroxylamine substituted imidazoquinolines
EP1658076B1 (en) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1660026A4 (en) 2003-09-05 2008-07-16 3M Innovative Properties Co Treatment for cd5+ b cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
NZ546273A (en) 2003-10-03 2009-05-31 Coley Pharm Group Inc Alkoxy substituted imidazoquinolines
AU2004291101A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
AR046781A1 (en) 2003-11-25 2005-12-21 3M Innovative Properties Co IMIDAZOQUINOLINE DERIVATIVES. PHARMACEUTICAL COMPOSITIONS.
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
EP1730143A2 (en) 2004-03-24 2006-12-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
CN101443005A (en) * 2004-12-30 2009-05-27 科勒制药集团公司 Immune response modifier formulations and methods
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006107851A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008535832A (en) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレイテッド Pyrazolopyridine-1,4-diamine and analogs thereof
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
CN101785857B (en) * 2010-03-05 2012-09-26 成都安特金生物技术有限公司 Novel pneumococcal conjugate vaccine and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375704T5 (en) * 2000-06-29 2016-03-03 Smithkline Beecham Biologicals S.A. Composition of multivalent vaccine

Also Published As

Publication number Publication date
AR046840A1 (en) 2005-12-28
WO2005049076A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
CU23404A1 (en) NEISSERIA MENINGITIDIS CAPSULAR POLYSACARIDS AS MUCOSOPT IMMUNOPOTENTIZERS AND RESULTING FORMULATIONS
CY1115308T1 (en) VACCINE COMPOSITIONS CONTAINING AN IMMUNE SAPONIN EXCIPIENT
EP3058954A3 (en) Immunogenic compositions and methods
ATE503493T1 (en) INFLUENZA VACCINE COMPOSITIONS FOR INTRADERMAL ADMINISTRATION
MX2018013640A (en) PEGILATED LIPOSOMES AND METHODS OF USE.
MX340096B (en) Meningococcal vaccine formulations.
CY1118732T1 (en) GNA1870 BASIC VACCINES VACCINE FOR WIDE-SPECT PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
PT1187629E (en) ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE
Riedl et al. The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
CY1111916T1 (en) VACCINATED VACCINATED ROTAIUS VACCINE FOR ADMINISTRATION OF THE ORAL
CR10559A (en) INFLUENZA VACCINE
DOP2009000239A (en) WATER OIL EMULSION INFLUENZA VACCINE
PE20190458A1 (en) NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS OF THE SAME
AR082952A1 (en) NEISSERIA MENINGITIDIS ORF2086 ANTIGEN VARIANTS OF ANTIGENS
UY27843A1 (en) VACCINE COMPOSITION
EA200601761A1 (en) COMPOSITIONS AS ADJUVANTS FOR STRENGTHENING IMMUNE RESPONSES TO VACCINES AND METHODS OF THEIR USE
BRPI0510430A (en) compositions and methods for mucosal vaccination
AR053661A1 (en) PEPTIDE TO DELIVER VACCINES VIA MUCOSAS
RU2008144180A (en) MYCOPLASMA VACCINE AND PRRSV
AR038311A1 (en) SURFACE ANTIGEN OF THE HEPATITIS B VIRUS AS A MUCOSOPT IMMUNOPOTENTIATOR, RESULTS FORMULATIONS
AR059972A1 (en) VIROSOMAS INTRANASAL OR INHALATIONAL ADMINISTRATION
UY28706A1 (en) PROTEOLIPOSOMAS AND ITS DERIVATIVES AS INDUCTING ASSISTANTS OF CYTOTOX RESPONSE AND THE RESULTING FORMULATIONS
AR046921A1 (en) METHOD FOR THE INCORPORATION OF ANTIGENS IN EXTERNAL MEMBRANE VESICULES OF BACTERIA AND RESULTING FORMULATIONS
TH75448A (en) Neisseria meningitidis-sheathed polysaccharides as an immunosuppressant of mucous membranes. And the formula for mixing the results obtained